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We describe a young woman with longstanding resistant hypertension. Evaluation for renal artery stenosis and primary
aldosteronism was unrevealing. In this setting of a suppressed plasma aldosterone concentration (PAC) and a suppressed plasma
renin activity (PRA), a diﬀerential diagnosis of a deoxycorticosterone (DOC) producing tumor was entertained. Biochemical and
imagingstudiesconﬁrmedthisdiagnosis.RareandnovelDOCproducingtumorsareanimportantcauseofresistanthypertension.
1.Introduction
Hypertension is a ubiquitous health problem. The overall
worldwide prevalence of hypertension in the adult popula-
tion is around 26% [1]. A signiﬁcant proportion of these
individuals have hypertension that is diﬃcult to control with
conventional treatment. Such patients are more likely to
have an underlying identiﬁable cause of hypertension [2].
Identiﬁcation of these causes is therefore acquiring greater
therapeutic importance for the clinician.
2. Case Presentation
A 35-year-old African American female presented to the
University Clinic for evaluation of resistant hypertension.
Shehadonsetofhypertensionattheageof17yearsandsince
then had suboptimally controlled blood pressure despite the
use of 4 antihypertensive medications including a diuretic.
When ﬁrst seen in the clinic, she was 3 weeks post partum
from delivery of a preterm infant due to preeclampsia. Her
only complaint in the oﬃce was that of fatigue which was
present even before pregnancy. Family history was positive
for hypertension in her mother and maternal grandfather,
developing in middle age. Medications included Lisinopril
20mg daily, Hydrochlorthiazide 25mg daily, Amlodipine
10mg daily, and Doxazosin 1mg at bedtime.
On examination, her blood pressure was 150/90mmHg
with a heart rate was 88. Physical examination was unre-
markable other than trace pedal edema. There were no
cushingoid features or virilisation noted on exam. Pertinent
laboratory values included a serum sodium of 135 (137–
144meq/L), serum potassium 3.1 (3.6–5.1meq/L), serum
bicarbonate of 26 (22–26meq/L), blood urea nitrogen 9
(8–24mg/dL), and serum creatinine of 0.8 (0.6–1.2mg/dL).
At this ﬁrst visit the patient received oral potassium sup-
plementation, Lisinopril dose was increased to 40mg daily
and Amiloride 5mg twice daily was added to the regimen.
Despite these measures patient continued to have poorly
controlled blood pressure.
Prior to referral to us, for evaluation of uncontrolled
hypertension accompanied by hypokalemia in a young
female, Magnetic Resonance Angiography (MRA) of the
renalarteriestolookforﬁbromusculardysplasiawasordered
by her treating physician. The MRA did not show any
evidence of renal artery stenosis. The MRA also did not
show any adrenal mass, though this investigation was done
primarily to screen for a vascular lesion and would not
deﬁne a mass as well as a conventional MRI. As we will
highlight in the following sections, based on the results of
her biochemical studies, this diagnosis was in fact, less likely
and this would not have been our initial screening test.
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Figure 1:Adrenalcorticaladenomademonstratingfocalhighgrade
nuclear atypia.
Figure 2 :A d r e n a lc o r t i c a la d e n o m aw i t ha r e a so ff o c a ln e c r o s i s .
plasma aldosterone concentration (PAC), and plasma renin
activity (PRA) levels were ordered. The PAC was suppressed
at <4.0ng/dL and the PRA level was also suppressed at
<0.6ng/mL/hr (0.6–4.0). In view of the suppressed PAC and
PRA levels, the patient underwent a 24-hour urine collection
for free cortisol and a plasma deoxycorticosterone (DOC)
level was checked. The 24-hour urine collection was signiﬁ-
cantforanelevatedfreecortisollevelof219(<45.0mcg/day).
The plasma deoxycorticosterone (DOC) levels were also
markedly elevated at 65 (1.6–5.6ng/dL). This leads us to
suspect the presence of a cortisol and deoxycorticosterone
cosecreting adrenal tumor. Subsequently a CT scan of the
abdomen with intravenous contrast was done. It showed a
5.3cm × 4.5cm × 7cm mass inferior to the right adrenal
gland. The patient underwent a laparoscopic partial right
adrenalectomy.
Histology revealed a right adrenal cortical adenoma on
frozen section. While there was focal high grade nuclear
atypia and focal necrosis, the ﬁndings were below the
threshold for malignancy (see Figures 1 and 2). Three
months postresection, patient had normalization of DOC
and urine free cortisol levels. She also exhibited marked
improvement in blood pressure control and was tapered oﬀ
all her hypertensive medications. Her blood pressure was
recorded at 100/50mmHg at followup.
3. Discussion
Our approach towards patients with resistant hypertension
involves obtaining a plasma renin activity (PRA) and a
plasma aldosterone concentration (PAC) as an initial step.
This helps separate patients into one of three categories:
(1) Those with a high PAC : PRA ratio; (2) those with a
high PAC and high PRA, and (3) those with a low PAC and
PRA levels. This is based on a high PAC : PRA ratio deﬁned
as >20 [3], and a high PAC value of ≥16ng/dL [4].
(1) H i g hP A C:P R AR a t i o .The principal diagnosis here is of
primary aldosteronism. The high PAC : PRA ratio is a good
screening test but it is not diagnostic of this disorder. Further
conﬁrmation is provided by the aldosterone suppression
test. Patients are salt-loaded either by mouth for 3 days
or intravenously. The 24-hour urinary sodium excretion
should be >200mEq to document adequate sodium reple-
tion. Urinary aldosterone excretion >12mg/24 hours is
consistent with hyperaldosteronism [3]. Once conﬁrmed,
patients need further testing with selective adrenal venous
sampling for aldosterone to distinguish unilateral aldos-
terone producing adenomas (APA) from bilateral idiopathic
hyperaldosteronism (IHA) [5]. The treatment of IHA is
pharmacologicwithuseofmineralocorticoidreceptorblock-
ers while APA is treated surgically with unilateral total
adrenalectomy.
(2) High PAC : High PRA. Patients presenting with a high
PAC accompanied by a high PRA are further worked up
for the presence of a unilateral renal artery stenosis or
more rarely for a renin-secreting tumor. Renal arteriogra-
phy remains the gold standard for diagnosis renal artery
stenosis. Patients with ﬁbromuscular disease respond better
to angioplasty than those with atherosclerotic disease [6].
Renin secreting tumors are rare entities arising from the
juxtaglomerular cells and are detected by radiologic imaging
of the abdomen [7].
(3) Low PAC : Low PRA. The presence of a low PAC
accompanied by a low PRA, as was present in our patient
leads to diﬀerential diagnosis of bilateral renal artery
stenosis, Cushing’s syndrome, congenital adrenal hyper-
plasia (CAH), apparent mineralocorticoid excess (AME),
deoxycorticosterone (DOC) producing tumors, and Liddle’s
syndrome. Cushing’s syndrome can be caused either by
excess endogenous cortisol or iatrogenically by excess steroid
administration. A urinary-free cortisol level four times
greater than normal is diagnostic of this disorder [8].
Apparent mineralocorticoid excess (AME) is a rare disorder
causing a severe form of early onset hypertension. It is
transmitted as an autosomal recessive trait. Patients suﬀer
from a deﬁciency of 11β-hydroxysteroid dehydrogenase type
2 enzyme. This enzyme normally converts the more active
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deﬁciency, cortisol continues to ﬂood the mineralocorticoid
receptor causing sodium retention, potassium wasting, and
hypertension. This syndrome is commonly found in settings
of familial consanguinity and there is extensive target organ
damage, nephrocalcinosis, and renal failure [9]. Our patient
did not have these clinical features including consanguinity
andrenalfailure. Ifurine cortisol levelsarenotelevated, then
as the next step, we check serum deoxycorticosterone (DOC)
levels. If elevated, as was present in this case, the diﬀerential
is that of CAH versus a DOC producing tumor. CAH is
most commonly caused due to 21 hydroxylase deﬁciency
and this is not associated with hypertension. CAH due to
deﬁciency of 11β-hydroxylase is seen most in the Middle
East and is characterized by virilization of the infant and 17-
hydroxylase enzyme deﬁciency is often manifest at birth and
is also mainly seen in pediatric populations. However, partial
enzyme deﬁciencies have been observed in hirsute women
[10]. Thus in adult patients, congenital enzymatic defects are
less likely compared to the likelihood of a DOC-producing
tumor. This is investigated further with imaging of the
abdomen. In the literature, DOC-producing tumors have
beendescribedonlyinahandfulofcases[11].Inourpatient,
CT scan of the abdomen did indeed reveal an adrenal mass.
Finally, if all testing is negative, the diagnosis of Liddle’s syn-
drome is entertained. These patients have a mutation of the
β orγ subunitoftherenalepithelialsodiumchannel,causing
is increased sodium reabsorption in the distal nephron [12].
This leads to manifestations similar to mineralocorticoid
excess, such as hypertension, hypokalemia, and metabolic
alkalosis. However, plasma renin activity and plasma aldos-
terone concentrations are secondarily suppressed in these
patients. Treatment consists of blocking distal nephron
sodium channels with drugs like amiloride and triamterene.
Inconclusion,inpatientswithresistanthypertensionaccom-
panied by low PRA and low PAC, Cushing’s syndrome
is an important diagnosis to be considered. If, however,
Cushing’s syndrome is ruled out, then in adult patients,
rare deoxycorticosterone producing tumors are a distinct
possibility.
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